A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-Term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular Ultrasonography
Phase 4
- Conditions
- Hypercholesteremia
- Registration Number
- JPRN-jRCT1080220348
- Lead Sponsor
- AstraZeneca/Shionogi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Ages Eligible for Study: 20 Years - 75 Years
Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Signed written informed consent,
- 20 to 75 years old,
- Plan to undergo coronary angiography (CAG) or PCI and LDL-C = 140 mg/dL (untreated patients) or LDL-C =100 mg/dL (treated patients
Exclusion Criteria
- Acute myocardial infarction within 72 hours after the onset,
- Heart failure of NYHA Class III or above,
- Serious arrhythmia,
- Being treated with LDL-apheresis
- History of serious reaction or hypersensitivity to other HMG-CoA reductase inhibitors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method